Source-grounded facts extracted from Viking Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Viking Therapeutics, Inc. shareholders approved Approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement at the 2026-05-19 meeting.
“Proposal No. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 30,045,938 12,763,135 401,396 36,879,063”
Viking Therapeutics, Inc. shareholders approved Ratify the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-19 meeting.
“Proposal No. 2. To ratify the selection of CBIZ CPAs P.C. as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 78,368,957 1,241,969 478,606”
Viking Therapeutics, Inc. shareholders approved Elect J. Matthew Singleton and S. Kathryn Rouan, Ph.D. as Class II directors at the 2026-05-19 meeting.
“Proposal No. 1. To elect the following nominees as Class II directors to serve until the Company’s 2029 annual meeting of stockholders or until such director’s respective successor is duly elected and qualified: Director Nominee Votes For Votes Withheld Broker Non-Votes J. Matthew Singleton 28,648,459 14,562,012 36,879,061 S. Kathryn Rouan, Ph.D. 21,960,203 21,250,268 36,879,061”
Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On April 29, 2026, we issued a press release reporting our financial results for the first quarter ended March 31, 2026 and providing a corporate update.”
Viking Therapeutics, Inc. engaged CBIZ CPAs P.C. as its auditor.
“(a) Resignation of Independent Registered Public Accounting Firm On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum LLP (“Marcum”), and substantially all of the partners and staff that provided attestation services with Marcum joined CBIZ in connection with the acquisition. Accordingly, on April 18, 2025, as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of Viking Therapeutics, Inc. (the “Company”) and, on April 22, 2025, the Audit Committee of the Company’s Board of Directors (the “Audit Committee”) approved the appointment of CBIZ as the Company’s independent registered public accounting firm. The reports of Marcum on the Company’s consolidated financial statements for the years ended December 31, 2024, and December 31, 2023, did not contain an adverse opinion or a disclaimer of opinion, and were not qu”
Marcum LLP resigned as auditor of Viking Therapeutics, Inc..
“on April 18, 2025, as a result of the acquisition, Marcum resigned as the independent registered public accounting firm of Viking Therapeutics, Inc.”
Viking Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.
“On April 24, 2024, we issued a press release reporting our financial results for the first quarter ended March 31, 2024 and providing a corporate update.”
Viking Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC valued at approximately $550.0 million (effective 2024-02-28).
“On February 28, 2024, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 6,471,000 shares of the Company’s common stock (“Common Stock”).”
Viking Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its clinical pipeline and other corporate developments.”
Viking Therapeutics, Inc. reported financial results for second quarter and six months ended June 30, 2023.
“On July 26, 2023, we issued a press release reporting our financial results for the second quarter and six months ended June 30, 2023 and providing a corporate update.”
Viking Therapeutics, Inc. shareholders rejected Approval of an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. at the 2023-06-13 meeting.
“Proposal No. 4. To approve an amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation: Votes For Votes Against Abstentions Broker Non-Votes 52,790,076 1,819,594 179,372 22,089,470 In order to be approved, this proposal required the affirmative vote of at least 66 2/3% of the voting power of all outstanding shares of the Company’s capital stock entitled to vote thereon. As a result, the Company’s stockholders did not approve the amendment to the Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.”
Viking Therapeutics, Inc. shareholders approved Advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. at the 2023-06-13 meeting.
“Proposal No. 3. To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 53,378,794 1,290,698 119,550 22,089,470 As a result, the Company’s stockholders voted to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.”
Viking Therapeutics, Inc. shareholders approved Ratification of the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023. at the 2023-06-13 meeting.
“Proposal No. 2. To ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023: Votes For Votes Against Abstentions 76,559,286 173,191 146,035 As a result, the Company’s stockholders voted to ratify the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023.”
Viking Therapeutics, Inc. shareholders approved Election of J. Matthew Singleton and S. Kathy Rouan, Ph.D. as Class II directors. at the 2023-06-13 meeting.
“Proposal No. 1. To elect the following nominees as Class II directors to serve until the Company’s 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified: Director Nominee Votes For Votes Withheld Broker Non-Votes J. Matthew Singleton 37,468,639 17,320,403 22,089,470 S. Kathy Rouan, Ph.D. 42,477,215 12,311,827 22,089,470 As a result, the Company’s stockholders voted to elect J. Matthew Singleton and S. Kathy Rouan, Ph.D. as Class II directors to serve until the Company’s 2026 annual meeting of stockholders or until his or her respective successor is duly elected and qualified.”
Viking Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, including compliance with Rule 14a-19, enhanced disclosure requirements, and other conforming changes (effective 2023-05-09).
“On May 9, 2023, the Board of Directors (the “Board”) of Viking Therapeutics, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date.”
Viking Therapeutics, Inc. reported financial results for first quarter ended March 31, 2023.
“announced its financial results for the first quarter ended March 31, 2023”
Viking Therapeutics, Inc. entered into Underwriting Agreement with William Blair & Company, L.L.C., as representative of the several underwriters valued at approximately $250.0 million (effective 2023-03-29).
“On March 29, 2023, Viking Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (the “Representative”), as representative of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of 17,242,000 shares of the Company’s common stock (“Common Stock”).”
Viking Therapeutics, Inc. reported financial results for fourth quarter and year ended December 31, 2022.
“On February 8, 2023, we issued a press release reporting our financial results for the fourth quarter and year ended December 31, 2022 and providing a corporate update.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.